The rapid drug susceptibility testing is a method that swiftly confirms resistance to Isoniazid (INH) and Rifampicin (RIF). It involves amplifying genes associated with resistance using PCR, then reacting with oligonucleotide probes to detect genetic mutations through Line Probe Assay (LPA).
Method
Line probe assay
Rifampicin Resistance
Detection of rpoB gene mutation
Isoniazid Resistance
Detection of katG mutation, as well as inhA and ahpC gene mutations
Insurance Code
D604203A[RIF] / D604204A[INH]
Classification Number
누-604나
Turnaround Time
Within 2 days
Requirement
Samples must be positive for culture or acid-fast bacilli (1+ or above)